Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
Evidence-based · Educational only
36+ Peptides indexed
Free research library
Free newsletter — subscribe below
★ = FDA-approved medical indication
Not medical advice — always consult a clinician
All peptides

PE-22-28

Also known as: Spadin analog
Research / Investigational

PE-22-28 is a shorter analog of spadin that blocks the TREK-1 potassium channel, an emerging target in depression research.

Buy PE-22-28 on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

PE-22-28 is a shorter analog of spadin that blocks the TREK-1 potassium channel, an emerging target in depression research.

FDA Approval Status

Not approved by the FDA. Investigational or intended for research purposes only.

Mechanism of Action

TREK-1 potassium channel inhibitor.

Current Research

Rodent models show antidepressant-like effects with rapid onset.
Research strength: Preliminary

Potential Medical Uses

  • Investigational only

Potential Benefits

  • Rapid antidepressant-like effect in animals

Known Side Effects

  • Unknown long-term human safety

Contraindications

  • Pregnancy

Drug Interactions

  • Not well characterized

Administration Methods

  • Subcutaneous or intranasal (research)

Half-life

Not well characterized

Reconstitution

Bacteriostatic water.

Storage & Handling

Refrigerated.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.